Private | |
Industry | Biotechnology |
Founded | April 2006 |
Founders | Linda Avey, Paul Cusenza and Anne Wojcicki |
Headquarters | Mountain View, California, United States |
Number of locations
|
3 |
Key people
|
Anne Wojcicki, CEO Esther Dyson, board member |
Products | Direct-to-consumer personal genome testing |
Services | Genetic testing, medical research |
Website | www |
23andMe is a privately held personal genomics and biotechnology company based in Mountain View, California. The company is named for the 23 pairs of chromosomes in a normal human cell. Its saliva-based direct-to-consumer personal genome test was named Invention of the Year by Time magazine in 2008.
In 2013 the US Food and Drug Administration (FDA) ordered 23andMe to discontinue marketing its personal genome service (PGS), as the company had not obtained the legally required regulatory approval. That resulted in concerns about the potential consequences of customers receiving inaccurate health results. The company continued to sell a personal genome test without health-related results in the United States until October 21, 2015, when it announced that it would be including a revised health component with FDA approval. 23andMe has been selling a product with both ancestry and health-related components in Canada since October 2014, and in the United Kingdom since December 2014.
The company was founded by Linda Avey, Paul Cusenza and Anne Wojcicki, ex-wife of Google founder Sergey Brin, in 2006 to provide genetic testing and interpretation to individual consumers. In 2007, Google invested $3,900,000 in the company, along with Genentech, New Enterprise Associates, and Mohr Davidow Ventures.
Cusenza left the company in 2007 and was appointed CEO of Nodal Exchange in 2008. Avey left the company in 2009 and co-founded Curious, Inc. in 2011.
In 2012, 23andMe raised $50 million in a Series D venture round, almost doubling its existing capital of $52.6 million. In 2015, 23andMe raised $115 million in a Series E offering, increasing its total capital to $241 million.